ArticleFrontiers in immunology2026
Propionate attenuates osteoarthritis progression by regulating the gut-joint axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut microbiota and osteoarthritis: mechanisms and translation.Frontiers in immunology · 2026Review
- Mechanistic insights into gut microbiota dysbiosis in osteoarthritis based on the gut-joint axis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis (OA) is a degenerative joint disorder characterized by cartilage degradation, inflammation, and pain. Growing evidence indicates that dysregulation of the gut-joint axis contributes to OA progression. This study investigated the therapeutic potential of propionate, a gut-derived short-chain fatty acid, in OA. Methods: A monosodium iodoacetate (MIA)-induced OA rat model was used to evaluate the effects of propionate on pain and inflammation through behavioral assessments, histological analysis, and gut microbiota profiling. The intestinal environment was further assessed by histology, tight junction protein analysis, and microbiota characterization. Human OA chondrocytes were analyzed using qPCR and RNA sequencing following IL-1β stimulation with or without propionate treatment. Results: Propionate attenuated OA severity in MIA-induced rats by improving pain behaviors, preserving cartilage structure, reducing nociceptive and inflammatory markers, and restoring intestinal barrier function and microbial balance. In human OA chondrocytes, propionate modulated inflammatory and ECM-related gene expression, promoted autophagy, and suppressed catabolic and inflammatory cell death pathways, highlighting its therapeutic potential in OA. Discussion: Propionate, a gut-derived SCFA, alleviated pain, protected cartilage, reduced inflammation, restored gut barrier integrity, and rebalanced microbiota in OA rats. In human OA chondrocytes, it upregulated ECM-related genes, downregulated inflammatory mediators, and enhanced autophagy. These findings suggest that propionate may serve as a promising disease-modifying therapy for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.